These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23419252)

  • 21. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanocarriers of antigen proteins for vaccine delivery.
    Lopes Chaves L; Dourado D; Prunache IB; Manuelle Marques da Silva P; Tacyana Dos Santos Lucena G; Cardoso de Souza Z; Muniz Mendes Freire de Moura P; Nunes Bordallo H; Rocha Formiga F; de Souza Rebouças J
    Int J Pharm; 2024 Jun; 659():124162. PubMed ID: 38663646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan-based drug nanocarriers: where do we stand?
    Garcia-Fuentes M; Alonso MJ
    J Control Release; 2012 Jul; 161(2):496-504. PubMed ID: 22480607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of nanocarriers for transdermal vaccine delivery.
    Lawson LB; Freytag LC; Clements JD
    Clin Pharmacol Ther; 2007 Dec; 82(6):641-3. PubMed ID: 17998911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticle vaccines.
    Zhao L; Seth A; Wibowo N; Zhao CX; Mitter N; Yu C; Middelberg AP
    Vaccine; 2014 Jan; 32(3):327-37. PubMed ID: 24295808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
    Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
    Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New vaccine introduction in the East and Southern African sub-region of the WHO African region in the context of GIVS and MDGs.
    Chauke-Moagi BE; Mumba M
    Vaccine; 2012 Sep; 30 Suppl 3():C3-8. PubMed ID: 22939018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in peptide-based subunit nanovaccines.
    Skwarczynski M; Toth I
    Nanomedicine (Lond); 2014 Dec; 9(17):2657-69. PubMed ID: 25529569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
    Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
    Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen uptake and immune responses after oral vaccination.
    Quentel C; Vigneulle M
    Dev Biol Stand; 1997; 90():69-78. PubMed ID: 9270836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced mucosal vaccination by biodegradable nanoparticles.
    Park K
    J Control Release; 2009 Sep; 138(2):89. PubMed ID: 19596033
    [No Abstract]   [Full Text] [Related]  

  • 33. Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.
    Peleteiro M; Presas E; González-Aramundiz JV; Sánchez-Correa B; Simón-Vázquez R; Csaba N; Alonso MJ; González-Fernández Á
    Front Immunol; 2018; 9():791. PubMed ID: 29725329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Particulate vaccines: on the quest for optimal delivery and immune response.
    De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
    Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal vaccination--an old but still vital strategy.
    Długońska H; Grzybowski M
    Ann Parasitol; 2012; 58(1):1-8. PubMed ID: 23094329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral vaccination and vaccine-entrapped microparticle delivery system].
    Li FQ; Fei YB; Su H; Hu JH
    Yao Xue Xue Bao; 2007 Mar; 42(3):245-51. PubMed ID: 17520821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.
    Wang S; Liu H; Zhang X; Qian F
    Protein Cell; 2015 Jul; 6(7):480-503. PubMed ID: 25944045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal immunization using recombinant plant-based oral vaccines.
    Streatfield SJ
    Methods; 2006 Feb; 38(2):150-7. PubMed ID: 16431131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Micro- and nanoparticle-based vaccines for hepatitis B.
    Bharali DJ; Mousa SA; Thanavala Y
    Adv Exp Med Biol; 2007; 601():415-21. PubMed ID: 17713030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.